Target intelligence / Profile preview

Endothelial transcription factor GATA-2 (GATA2)

Target
GATA2
Molecular classification
Transcription factor
01

Overview

Endothelial transcription factor GATA-2 (GATA2) is a zinc-finger transcription factor that plays a critical role in the development, proliferation, and maintenance of hematopoietic, endothelial, and endocrine cell lineages. It functions as a pioneer factor, binding to consensus DNA sequences to regulate gene expression, including the regulation of endothelin-1 in endothelial cells and the modulation of androgen receptor (AR) expression and activity in prostate cells. GATA2 is highly implicated in various diseases; germline mutations lead to GATA2 deficiency syndrome, characterized by immunodeficiency, lymphedema, and a high predisposition to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Conversely, overexpression of GATA2 is a key driver in castration-resistant prostate cancer (CRPC) and chemotherapy-resistant AML, making it an attractive therapeutic target. While there are currently no clinically approved drugs specifically targeting GATA2, small molecules like the repurposed vasodilator dilazep and the experimental compound K-7174 have demonstrated the ability to inhibit GATA2 activity, suppress downstream oncogenic pathways, and induce apoptosis in cancer cells. However, therapeutic targeting of GATA2 poses significant safety challenges, as systemic inhibition may impair normal hematopoiesis, exacerbate immunodeficiency, or cause vascular and thrombotic complications.

Other names
GATA-binding protein 2GATA binding protein 2GATA2hGATA2GATA2p
02

Mechanism of action

Inhibition of GATA2 DNA-binding activity, suppression of GATA2 recruitment to chromatin, and downregulation of downstream transcriptional programs

03

Biological functions

Transcription regulationCell differentiationAngiogenesisCell proliferation
04

Disease associations

CancerInfectionImmunodeficiencyCardiovascular diseaseOther
05

Safety considerations

MyelosuppressionImmunodeficiencyLymphedemaThrombotic eventsBone marrow failureVascular toxicity
06

Interacting drugs

2 more in the full profile.

07

Biomarkers

GATA2 expression levelAndrogen receptor expressionc-MYC expressionGATA2 mutation statusMonocytopeniaB-cell lymphopeniaNK-cell lymphopenia

Beyond the preview

Go deeper on Endothelial transcription factor GATA-2 (GATA2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endothelial transcription factor GATA-2 (GATA2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call